Patents Examined by Charanjit Aulakh
  • Compounds and methods for conjugation of biomolecules
    Patent number: 11067580
    Abstract: Low-copper click chemistry, 1.3-dipolar cycloadditions, and Staudinger ligations for modifying biomolecules is provided. Compositions, methods, and kits relating to low-copper click chemistry, 1.3-dipolar cycloadditions, and Staudinger ligations are also provided.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: July 20, 2021
    Assignee: Life Technologies Corporation
    Inventors: Kyle Gee, Upinder Singh, Scott Grecian, Scott Clarke
  • Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
    Patent number: 11065237
    Abstract: Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: July 20, 2021
    Assignee: Akebia Therapeutics, Inc.
    Inventors: James Densmore Copp, Ann W. Newman, Anne Luong
  • Streamlined syntheses of fluoroquinolones
    Patent number: 11059788
    Abstract: Methods of synthesizing fluoroquinolones such as ciprofloxacin are provided. The methods utilize affordable materials, reduce the number of synthesis steps and provide high yields.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: July 13, 2021
    Assignee: Virginia Commonwealth University
    Inventors: Frank B. Gupton, Perrer N. Tosso
  • Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof
    Patent number: 11058676
    Abstract: Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: July 13, 2021
    Assignee: PHARMAKEA, INC.
    Inventors: Martin W. Rowbottom, John Howard Hutchinson
  • MAGL inhibitors
    Patent number: 11059822
    Abstract: Provided herein are spirocyclic and fused bicyclic carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: July 13, 2021
    Assignee: H. LUNDBECK A/S
    Inventors: Cheryl A. Grice, Daniel J. Buzard, Michael B. Shaghafi
  • 4-azaindole compounds
    Patent number: 11053244
    Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: July 6, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Trevor C. Sherwood, Brian K. Whiteley, John L. Gilmore, Sreekantha Ratna Kumar, Laxman Pasunoori, Pitani Veera Venkata Srinivas, Srinivasan Kunchithapatham Duraisamy, Subramanya Hegde, Rushith Kumar Anumula
  • Inhibitors of (?-v)(?-6) integrin
    Patent number: 11046669
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: June 29, 2021
    Assignee: Morphic Therapeutic, Inc.
    Inventors: Bryce A. Harrison, Matthew G. Bursavich, Mark Brewer, Aleksey I. Gerasyuto, Kristopher N. Hahn, Kyle D. Konze, Fu-Yang Lin, Blaise S. Lippa, Alexey A. Lugovskoy, Bruce N. Rogers, Mats A. Svensson, Dawn M. Troast
  • Methods of treating food allergy conditions
    Patent number: 11045454
    Abstract: Methods for treating a subject for a food allergy condition are provided. Aspects of the methods include administering to a subject in need thereof a psychedelic agent in a manner effective to treat the subject for a food allergy condition. Effective administration of a psychedelic agent may include administering the psychedelic agent in an amount effective to treat the subject for the food allergy condition. In some instances, the subject is known to have a food allergy condition.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: June 29, 2021
    Assignee: Palo Alto Investors LP
    Inventors: Anthony Joonkyoo Yun, Conrad Minkyoo Yun
  • Inhibitors of (?-v)(?-6) integrin
    Patent number: 11046685
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: June 29, 2021
    Assignee: Morphic Therapeutic, Inc.
    Inventors: Bryce A. Harrison, Matthew G. Bursavich, Aleksey I. Gerasyuto, Kristopher N. Hahn, Kyle D. Konze, Fu-Yang Lin, Blaise S. Lippa, Alexey A. Lugovskoy, Bruce N. Rogers, Mats A. Svensson, Dawn M. Troast
  • Inhibitors of (alpha-v)(beta-6) integrin
    Patent number: 11040955
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: June 22, 2021
    Assignee: Morphic Therapeutic, Inc.
    Inventors: Mark Brewer, Matthew G. Bursavich, Aleksey I. Gerasyuto, Kristopher N. Hahn, Bryce A. Harrison, Kyle D. Konze, Fu-Yang Lin, Blaise S. Lippa, Alexey A. Lugovskoy, Bruce N. Rogers, Mats A. Svensson, Dawn M. Troast
  • Inhibitors of kinase networks and uses thereof
    Patent number: 11040973
    Abstract: The present invention generally relates to compounds as a dual kinase-demethylase inhibitor useful for the treatment of diseases mediated by a kinase and/or a histone demethylase, such as inflammation, cancer, viral and bacterial infections, neurological and immunological disorders. Pharmaceutical compositions and methods for treating those diseases are within the scope of this invention.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: June 22, 2021
    Inventors: Herman O. Sintim, Neetu Dayal, Clement Opoku-Temeng
  • CXCR3 receptor agonists
    Patent number: 11040954
    Abstract: Compounds are provided having the structure of the following Formula I: where R, R1, R2, R3a and R3b are as defined herein. Pharmaceutical compositions comprising such compounds, as well as methods related to their manufacture and use, are also provided.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: June 22, 2021
    Assignee: RECEPTOS LLC
    Inventors: Adam Yeager, Philip Turnbull, Lin Zhang, Junhua Fan, Junko Tamiya, Marcos Steinberg, Tom Fowler, Hanae Benelkebir, Raffaele Pasceri, Maria Ieva, Kevan Grant, Yang Tran
  • Pyrrole and pyrazole compounds and methods of use thereof
    Patent number: 11034669
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: June 15, 2021
    Assignee: Nuvation Bio Inc.
    Inventors: Sarvajit Chakravarty, Son Minh Pham, Jiyun Chen, Jayakanth Kankanala, Jeremy D. Pettigrew, Anjan Kumar Nayak, Anup Barde, Brahmam Pujala
  • Somatostatin modulators and uses thereof
    Patent number: 11028068
    Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: June 8, 2021
    Assignee: CRINETICS PHARMACEUTICALS, INC.
    Inventors: Jian Zhao, Yunfei Zhu, Shimiao Wang, Sangdon Han, Sun Hee Kim
  • Heteroaryl inhibitors of PAD4
    Patent number: 11026937
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: June 8, 2021
    Assignee: Padlock Therapeutics, Inc.
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Cristina Lecci, Pui Leng Loke, Mirco Meniconi, Nathaniel Julius Thomas Monck, Carl Leslie North, Mark Peter Ridgill, Heather Tye
  • Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
    Patent number: 11028067
    Abstract: There is provided compounds of formula I (I) or pharmaceutically-acceptable salts thereof, wherein L, R1, R2, R3 and X have meanings provided in the description, which compounds are useful in the treatment of cancers.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: June 8, 2021
    Assignee: Oblique Therapeutics AB
    Inventors: Benjamin Pelcman, Edgars Suna, William Stafford, Martins Priede
  • Therapeutic compounds
    Patent number: 11020380
    Abstract: The present embodiments relate to substituted heterocyclic derivative therapeutic compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of diseases mediated by aberrant cell signalling, such as inflammatory disorders, cancer and neoplastic disease. Particular compounds described herein exhibit selective inhibitory activity against CBP compared with BRD4.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: June 1, 2021
    Assignee: CELGENE QUANTICEL RESEARCH, INC.
    Inventors: Lynnie Trzoss, Juan Manuel Betancort, Toufike Kanouni, Michael Brennan Wallace, Amogh Boloor
  • Inhibiting (?-V)(?-6) integrin
    Patent number: 11021480
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: June 1, 2021
    Assignee: Morphic Therapeutic, Inc.
    Inventors: Bryce A. Harrison, James E. Dowling, Matthew G. Bursavich, Dawn M. Troast, Blaise S. Lippa, Bruce N. Rogers, Cheng Zhong, Qi Qiao, Fu-Yang Lin, Brian Sosa, Aleksey I. Gerasyuto, Andrea Bortolato
  • Cyclobutane- and azetidine-containing mono and spirocyclic compounds as ?V integrin inhibitors
    Patent number: 11014922
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: May 25, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pratik Devasthale, Fang Moore, Guohua Zhao, Susan Nicole Pieniazek, Kumaravel Selvakumar, Suresh Dhanusu, Manoranjan Panda, Lawrence R. Marcin
  • 2,6-disubstituted pyridine derivative
    Patent number: 11014905
    Abstract: The present invention relates to a pyridine derivative of formula (1) wherein R1 is optionally-substituted C1-6 alkyl, optionally-substituted C3-10 cycloalkyl, or optionally-substituted 5- to 10-membered saturated or partially-unsaturated heterocyclyl; R2 is halogen atom, cyano, C1-6 alkyl which may be optionally substituted with 1 to 3 the same or different halogen atoms, C1-6 alkoxy which may be optionally substituted with 1 to 3 the same or different halogen atoms, or amino which may be optionally substituted with 1 to 2 the same or different C1-6 alkyl; and the bind with broken line is single or double bond, or a pharmaceutically acceptable salt thereof, which is useful as a medicament for treating symptoms in anxiety-related disorder.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: May 25, 2021
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Hidefumi Yoshinaga, Hiro Uemachi, Tomomi Ohno, Jeremy Besnard